Abstract CT048: Phase 1/2 study of olaparib tablets and temozolomide in patients with small cell lung cancer (SCLC) following failure of prior chemotherapy
Anna F. Farago(Massachusetts General Hospital), Alice T. Shaw(Dana-Farber Cancer Institute), Christopher G. Azzoli(Massachusetts General Hospital), Nicholas J. Dyson(Massachusetts General Hospital), David A. Barbie(Dana-Farber Cancer Institute), Rebecca S. Heist(Massachusetts General Hospital), Shyamala Maheswaran(Massachusetts General Hospital), Edwin Choy(Massachusetts General Hospital), Lecia V. Sequist(Harvard University), Benjamin J. Drapkin(Southwestern Medical Center), Aaron N. Hata(Harvard University), David M. Jackman(Brigham and Women's Hospital), Daniel A. Haber(Howard Hughes Medical Institute), Beow Y. Yeap(Harvard University), Allison Charles(Massachusetts General Hospital)
Cited by 9
Related Papers
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
|Nature|2009|4.2k
Isolation of rare circulating tumour cells in cancer patients by microchip technology
|Nature|2007|3.5k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k